Back to top

Analyst Blog

Zacks Equity Research

Watson to Market Antares' OAB Drug

MKGAF

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Watson Pharmaceuticals Inc. recently announced that it has entered into a licensing agreement with Antares Pharma Inc. for the commercialization of Antares Pharma's topical oxybutynin gel in the US and Canada. The oxybutynin gel is currently under regulatory review in the US as a treatment for overactive bladder (OAB). The US Food and Drug Administration (FDA) is expected to give its decision on the approval of the product by December 8, 2011.

According to the agreement, Watson will be responsible for certain manufacturing start-up activities and will make payments to Antares Pharma on the achievement of milestones like gaining regulatory approval and reaching certain sales levels. Following the launch of oxybutynin gel, Antares Pharma will also be entitled to receive escalating royalties on the US and Canadian sales of the drug.

The phase III study results of oxybutynin gel demonstrated that patients dosed 56 mg or 84 mg of oxybutynin gel daily, experienced a statistically significant decrease in OAB symptoms, including the number of urinary incontinence episodes per day, compared to patients who received placebo.

We believe this deal will enhance Watson Pharma’s proprietary drug portfolio, which recently was strengthened by the FDA accepting the company’s New Drug Application (NDA) for Prochieve (progesterone gel). Prochieve has been developed in partnership with Columbia Laboratories Inc. for the reduction of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.

Watson Pharma had acquired the US rights to Prochieve from Columbia Labs in July last year. Along with Prochieve, Watson Pharma also acquired the US rights to Crinone. On Crinone, which is indicated for the treatment of infertility in women, Columbia Labs receives royalties on net sales made by Watson Pharma. Outside the US, Crinone is marketed by Merck KGaA (MKGAF).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%